{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:08:48Z","timestamp":1707523728247},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,9]]},"DOI":"10.7759\/cureus.13246","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T21:07:42Z","timestamp":1612904862000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Monoclonal Antibody \"Alemtuzumab\" in the Treatment of Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Sadia","family":"Nosher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sehrish","family":"Fuad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nupur","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaid A","family":"Alrashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bindu","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devyani","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak M","family":"Basavanagowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arveen","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey E","family":"Heindl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Multiple Sclerosis. Who gets MS? (Epidemiology). (2018). Accessed. October 24, 2018: https:\/\/www.nationalmssociety.org\/What-is-MS\/Who-Gets-MS."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19+CD24hiCD38hi cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair PA","year":"2010","unstructured":"Blair PA, Norena LY, Flores-Borja F, et al.. CD19+CD24hiCD38hi cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. 2010, 32:129-140. 10.1016\/j.immuni.2009.11.009"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6997","article-title":"PD-L1hi B cells are critical regulators of humoral immunity","volume":"6","author":"Khan AR","year":"2015","unstructured":"Khan AR, Hams E, Floudas A, et al.. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun. 2015, 6:5997. 10.1038\/ncomms6997","journal-title":"Nat Commun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134523","article-title":"Circulating CCR7+ICOS+ memory T follicular helper cells in patients with multiple sclerosis","volume":"10","author":"Fan X","year":"2015","unstructured":"Fan X, Jin T, Zhao S, et al.. Circulating CCR7+ICOS+ memory T follicular helper cells in patients with multiple sclerosis. PLoS One. 2015, 10:0134523. 10.1371\/journal.pone.0134523","journal-title":"PLoS One"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu Y","year":"2009","unstructured":"Hu Y, Turner MJ, Shields J, et al.. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009, 128:260-270. 10.1111\/j.1365-2567.2009.03115.x","journal-title":"Immunology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.04.018","article-title":"Immune status following alemtuzumab treatment in human CD52 transgenic mice","volume":"261","author":"Turner MJ","year":"2013","unstructured":"Turner MJ, Lamorte MJ, Chretien N, et al.. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol. 2013, 261:29-36. 10.1016\/j.jneuroim.2013.04.018","journal-title":"J Neuroimmunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.04.006","article-title":"Immune mechanisms of new therapeutic strategies in multiple sclerosis: a focus on alemtuzumab","volume":"142","author":"Klotz L","year":"2012","unstructured":"Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis: a focus on alemtuzumab. Clin Immunol. 2012, 142:25-30. 10.1016\/j.clim.2011.04.006","journal-title":"Clin Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab","volume":"74","author":"Baker D","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, et al.. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017, 74:961-969. 10.1001\/jamaneurol.2017.0676","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"CAMMS223 Trial Investigators; Coles AJ","year":"2008","unstructured":"CAMMS223 Trial Investigators; Coles AJ, Compston DAS, Selmaj KW, et al.. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008, 359:1786-1801. 10.1056\/NEJMoa0802670","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial","volume":"380","author":"Cohen JA","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al.. Alemtuzumab versus interferon beta 1a as first-line treatment for patients relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet. 2012, 380:1819-1828. 10.1016\/S0140-6736(12)61769-3","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial","volume":"380","author":"Coles AJ","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al.. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet. 2012, 380:1829-1839. 10.1016\/S0140-6736(12)61768-1","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30076-6","article-title":"Intracerebral hemorrhage during alemtuzumab administration","volume":"18","author":"Azevedo CJ","year":"2019","unstructured":"Azevedo CJ, Kutz C, Dix A, et al.. Intracerebral hemorrhage during alemtuzumab administration. Lancet Neurol. 2019, 18:329-331. 10.1016\/S1474-4422(19)30076-6","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.012","article-title":"Revised diagnostic criteria of multiple sclerosis","volume":"13","author":"Milo R","year":"2014","unstructured":"Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmun Rev. 2014, 13:518-524. 10.1016\/j.autrev.2014.01.012","journal-title":"Autoimmun Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of \u00admultiple sclerosis","volume":"13","author":"Fisniku LK","year":"2008","unstructured":"Fisniku LK, Brex PA, Altmann DR, et al.. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of \u00admultiple sclerosis. Brain. 2008, 13:808-817. 10.1093\/brain\/awm329","journal-title":"Brain"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann H","year":"2007","unstructured":"Lassmann H, Br\u00fcck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218. 10.1111\/j.1750-3639.2007.00064.x","journal-title":"Brain Pathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.168","article-title":"Progressive multiple sclerosis: pathology and pathogenesis","volume":"8","author":"Lassmann H","year":"2012","unstructured":"Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012, 8:647-656. 10.1038\/nrneurol.2012.168","journal-title":"Nat Rev Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.43.4.655","article-title":"The IFNB Multiple Sclerosis Study Group: interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"43","author":"Duquette P","year":"1993","unstructured":"Duquette P, Girard M, Despault L. The IFNB Multiple Sclerosis Study Group: interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993, 43:655-661. 10.1212\/wnl.43.4.655","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier BC","year":"2011","unstructured":"Kieseier BC. The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis. CNS Drugs. 2011, 25:491-502. 10.2165\/11591110-000000000-00000","journal-title":"CNS Drugs"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.05.005","article-title":"Immunomodulation neuroprotection and remyelination\u2014glatiramer acetate's fundamental therapeutic effects: a critical review","volume":"54","author":"Aharoni R","year":"2014","unstructured":"Aharoni R. Immunomodulation neuroprotection and remyelination\u2014glatiramer acetate's fundamental therapeutic effects: a critical review. J Autoimmun. 2014, 54:81-92. 10.1016\/j.jaut.2014.05.005","journal-title":"J Autoimmun"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.337","article-title":"Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies","volume":"5","author":"Guillermo I","year":"2015","unstructured":"Guillermo I, Nuria S, Macarena R, et al.. Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies. Brain Behav. 2015, 5:00337. 10.1002\/brb3.337","journal-title":"Brain Behav"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.05.005","article-title":"Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy","volume":"142","author":"Ingwersen J","year":"2012","unstructured":"Ingwersen J, Aktas O, Kuery P, et al.. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol. 2012, 142:15-24. 10.1016\/j.clim.2011.05.005","journal-title":"Clin Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2015.03.006","article-title":"Sphingosine 1-phosphate signaling at the blood-brain barrier","volume":"21","author":"Prager B","year":"2015","unstructured":"Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med. 2015, 21:354-363. 10.1016\/j.molmed.2015.03.006","journal-title":"Trends Mol Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0167-z","article-title":"No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis","volume":"31","author":"Nixon R","year":"2014","unstructured":"Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014, 31:1134-1154.  10.1007\/s12325-014-0167-z","journal-title":"Adv Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24339","article-title":"Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis","volume":"77","author":"Kalincik T","year":"2015","unstructured":"Kalincik T, Horakova D, Spelman T, et al.. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015, 77:425-435.  10.1002\/ana.24339","journal-title":"Ann Neurol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0412-4","article-title":"Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis","volume":"13","author":"Ingwersen J","year":"2016","unstructured":"Ingwersen J, Aktas O, Hartung HP. Advances in and algorithms for the treatment of relapsing-remitting multiple sclerosis. Neurotherapeutics. 2016, 13:47-57. 10.1007\/s13311-015-0412-4","journal-title":"Neurotherapeutics"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman CH","year":"2006","unstructured":"Polman CH, O'Connor PW, Havrdova E, et al.. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006, 354:899-910. 10.1056\/NEJMoa044397","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2010.0089","article-title":"Current and future role of interferon-beta in the therapy of multiple sclerosis","volume":"30","author":"Farrell RA","year":"2010","unstructured":"Farrell RA, Giovannoni G. Current and future role of interferon-beta in the therapy of multiple sclerosis. J Interferon Cytokine Res. 2010, 30:715-726. 10.1089\/jir.2010.0089","journal-title":"J Interferon Cytokine Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.013","article-title":"Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies","volume":"12","author":"Kita M","year":"2014","unstructured":"Kita M, Fox RJ, Gold R, et al.. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies. Clin Ther.  2014, 12:1958-1971. 10.1016\/j.clinthera.2014.08.013","journal-title":"Clin Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.04.014","article-title":"Neutropenia with fatal outcome in multiple sclerosis patient 23 days after alemtuzumab infusion","volume":"23","author":"Yiannopoulou KG","year":"2018","unstructured":"Yiannopoulou KG, Papadimitriou D, Anastasiou AI, Siakantaris M. Neutropenia with fatal outcome in multiple sclerosis patient 23 days after alemtuzumab infusion. Mult Scler Relat Disord. 2018, 23:15-16. 10.1016\/j.msard.2018.04.014","journal-title":"Mult Scler Relat Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0352-1","article-title":"Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis","volume":"4","author":"Metz I","year":"2016","unstructured":"Metz I, Rieckmann P, Kallmann BA, Bruck W. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis. Acta Neuropathol Commun. 2016, 4:81. 10.1186\/s40478-016-0352-1","journal-title":"Acta Neuropathol Commun"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani N","year":"2018","unstructured":"Pariani N, Willis M, Muller I, et al.. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018, 103:3010-3018. 10.1210\/jc.2018-00359","journal-title":"J Clin Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37878","article-title":"IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)","volume":"119","author":"Jones JL","year":"2009","unstructured":"Jones JL, Phuah CL, Cox AL, et al.. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009, 119:2052-2061. 10.1172\/JCI37878","journal-title":"J Clin Invest"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment multiple sclerosis","volume":"83","author":"Hill-Cawthorne GA","year":"2012","unstructured":"Hill-Cawthorne GA, Button T, Tuohy O, et al.. Long term lymphocyte reconstitution after alemtuzumab treatment multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012, 83:298-304. 10.1136\/jnnp-2011-300826","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.5","article-title":"Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis","volume":"12","author":"Costelloe L","year":"2012","unstructured":"Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012, 12:335-341. 10.1586\/ern.12.5","journal-title":"Expert Rev Neurother"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228bec5","article-title":"Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort","volume":"77","author":"Coburn M","year":"2011","unstructured":"Coburn M, Pace AA, Jones J, et al.. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011, 77:573-579. 10.1212\/WNL.0b013e318228bec5","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S140481","article-title":"Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown","volume":"9","author":"Moss HE","year":"2017","unstructured":"Moss HE. Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown. Eye Brain. 2017, 9:13-21. 10.2147\/EB.S140481","journal-title":"Eye Brain"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0232.correx","article-title":"Correction to: Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that TRAb may precede thyroid dysfunction by many years","volume":"29","author":"Muller I","year":"2019","unstructured":"Muller I, Willis M, Healy S, et al.. Correction to: Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that TRAb may precede thyroid dysfunction by many years. Thyroid. 2019, 29:309. 10.1089\/thy.2018.0232.correx","journal-title":"Thyroid"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein JD","year":"2015","unstructured":"Stein JD, Childers D, Gupta S, et al.. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 2015, 133:290-296. 10.1001\/jamaophthalmol.2014.5103","journal-title":"JAMA Ophthalmol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0934-5","article-title":"The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy","volume":"253","author":"Coles AJ","year":"2006","unstructured":"Coles AJ, Cox A, Le Page E, et al.. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006, 253:98-108. 10.1007\/s00415-005-0934-5","journal-title":"J Neurol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005420","article-title":"Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab","volume":"90","author":"Saarela M","year":"2018","unstructured":"Saarela M, Senthil K, Jones J, et al.. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018, 90:849-851. 10.1212\/WNL.0000000000005420","journal-title":"Neurology"},{"key":"ref41","unstructured":"US FDA Lemtrada. prescribing information. (2017). Accessed: June 16, 2017: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103948s5139lbl.pdf."},{"key":"ref42","unstructured":"EMA summary of the product of characteristics. (2017). Accessed. June 16, 2017: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/003718\/WC500150521.pdf..."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102146","article-title":"Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program","volume":"43","author":"Achiron A","year":"2020","unstructured":"Achiron A, Chambers C, Fox EJ, et al.. Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. Mult Scler J. 2020, 43:581-582. 10.1016\/j.msard.2020.102146","journal-title":"Mult Scler J"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2014-030","article-title":"Prevention and management of infusion-associated reactions in comparing Alemtuzumab and Rebif\u00ae efficacy in multiple Sclerosis (CARE-MS) program","volume":"17","author":"Canon C","year":"2015","unstructured":"Canon C, Namey M, Meyer C, et al.. Prevention and management of infusion-associated reactions in comparing Alemtuzumab and Rebif\u00ae efficacy in multiple Sclerosis (CARE-MS) program. Int J MS Care. 2015, 17:191-198. 10.7224\/1537-2073.2014-030","journal-title":"Int J MS Care"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1188\/07.CJON.S1.37-42","article-title":"Cytokine-release syndrome: overview and nursing implications","volume":"11","author":"Breslin S","year":"2007","unstructured":"Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007, 11:37-42. 10.1188\/07.CJON.S1.37-42","journal-title":"Clin J Oncol Nurs"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/47325-role-of-monoclonal-antibody-alemtuzumab-in-the-treatment-of-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:30:17Z","timestamp":1707507017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/47325-role-of-monoclonal-antibody-alemtuzumab-in-the-treatment-of-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.13246","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,9]]}}}